# X-Linked Agammaglobulinemia (XLA)

### Disease Overview
X-Linked Agammaglobulinemia (XLA) is a rare primary immunodeficiency disorder characterized by the absence or severely reduced production of immunoglobulins (antibodies) due to a genetic mutation affecting B cell development. This condition significantly impairs the body's ability to fight bacterial infections, particularly in infants and young children.

### Disease Category
Primary Immunodeficiency Disorder (Humoral Immunodeficiency)

### Synonyms
- Bruton Agammaglobulinemia
- Congenital Agammaglobulinemia
- XLA
- BTK Deficiency

### Signs & Symptoms
- Recurrent bacterial infections
- Frequent pneumonia
- Chronic sinusitis
- Repeated ear infections
- Poor response to vaccinations
- Decreased or absent tonsils and lymph nodes
- Increased susceptibility to respiratory tract infections
- Potential chronic lung damage from repeated infections
- Higher risk of autoimmune disorders
- Potential gastrointestinal infections

### Causes
- Mutations in the BTK (Bruton tyrosine kinase) gene located on the X chromosome
- X-linked recessive inheritance pattern
- Genetic defect prevents normal B cell maturation and antibody production
- Complete absence or significant reduction of mature B lymphocytes

### Affected Populations
- Exclusively affects males
- Estimated prevalence: 1 in 190,000 to 250,000 live male births
- Typically diagnosed in infancy or early childhood
- Genetic carriers are typically asymptomatic females

### Disorders with Similar Symptoms
- Common Variable Immunodeficiency (CVID)
- Hyper IgM syndrome
- Severe Combined Immunodeficiency (SCID)
- Chronic Granulomatous Disease (CGD)
- Selective IgA Deficiency

### Diagnosis
- Comprehensive medical history and physical examination
- Serum immunoglobulin level testing
- Flow cytometry to assess B cell numbers
- Genetic testing for BTK gene mutations
- Complete blood count
- Immunological function tests
- Screening for potential infections

### Standard Therapies
- Lifelong immunoglobulin replacement therapy
- Intravenous (IVIG) or subcutaneous (SCIG) immunoglobulin administration
- Prophylactic antibiotics
- Aggressive treatment of infections
- Regular medical monitoring
- Vaccination strategies (with inactivated vaccines)

### Clinical Trials and Studies
- Ongoing research in gene therapy
- Investigations into targeted BTK enzyme replacement
- Studies exploring novel immunoglobulin delivery methods
- Potential future treatments focusing on genetic correction

### References
- Primary Immunodeficiency Resource Center
- National Institutes of Health (NIH)
- Jeffrey Modell Foundation Medical Research Database
- World Health Organization (WHO) Immunodeficiency Guidelines

### Programs & Resources
- Immune Deficiency Foundation (IDF)
- Jeffrey Modell Foundation
- National Organization for Rare Disorders (NORD)
- Genetic and Rare Diseases (GARD) Information Center
- Patient support groups and online communities

### Complete Report
Comprehensive management requires multidisciplinary care involving immunologists, pediatricians, and genetic counselors. Early diagnosis and consistent treatment are crucial for managing XLA and preventing long-term complications.